Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
domvanalimab
(AB154) /
Arcus Biosci, Gilead
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
«
1
2
3
|
|||||||||
Trodelvy
(sacituzumab govitecan-hziy) /
Gilead
Enrollment open, Metastases:
TROPHY-U-01: Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
(clinicaltrials.gov) - Nov 9, 2018
P2
, N=140, Recruiting,
Sponsor: Immunomedics, Inc.
Not yet recruiting --> Recruiting
|
|||||||||
domvanalimab
(AB154) /
Arcus Biosci, Gilead
Enrollment open, Combination therapy, Monotherapy, Metastases:
A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
(clinicaltrials.gov) - Aug 15, 2018
P1
, N=42, Recruiting,
Sponsor: Arcus Biosciences, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
|
|||||||||
domvanalimab
(AB154) /
Arcus Biosci, Gilead
New P1 trial, Combination therapy, Monotherapy, Metastases:
A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
(clinicaltrials.gov) - Aug 13, 2018
P1
, N=42, Not yet recruiting,
Sponsor: Arcus Biosciences, Inc.
||||
||||||
Trodelvy
(sacituzumab govitecan-hziy) /
Gilead
New P2 trial, Metastases:
TROPHY-U-01: Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
(clinicaltrials.gov) - Jul 15, 2018
P2
, N=140, Not yet recruiting,
Sponsor: Immunomedics, Inc.